Nykode Therapeutics As (VACBF)

$0.19 -0.01 (-5.82%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 200
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 0%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 ind...

Industry: Biotechnology
Sector: Healthcare
Phone: 47 22 95 81 93
Website: nykode.com
Address:
Oslo Research Park, Gaustadalleen 21, Oslo, Norway
Putoelquelolea2
Putoelquelolea2 May. 28 at 2:00 PM
$VACBF There was a very strong, unjustified sale just to eliminate dividends, but there's no data that degrades the company's value, it was just an overreaction on the part of the market. It also has no debt, which is very positive. I see a 20% increase for next week📈✅
0 · Reply
MarketBeat
MarketBeat Aug. 31 at 11:15 AM
Nykode Therapeutics AS initiated by HC Wainwright at buy. www.marketbeat.com/stocks/OTCMKTS/VACBF/price-target/ $VACBF
0 · Reply
Latest News on VACBF
No data available.
Putoelquelolea2
Putoelquelolea2 May. 28 at 2:00 PM
$VACBF There was a very strong, unjustified sale just to eliminate dividends, but there's no data that degrades the company's value, it was just an overreaction on the part of the market. It also has no debt, which is very positive. I see a 20% increase for next week📈✅
0 · Reply
MarketBeat
MarketBeat Aug. 31 at 11:15 AM
Nykode Therapeutics AS initiated by HC Wainwright at buy. www.marketbeat.com/stocks/OTCMKTS/VACBF/price-target/ $VACBF
0 · Reply